Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 223.7 INR 0.55% Market Closed
Market Cap: 710.7B INR
Have any thoughts about
Aurobindo Pharma Ltd?
Write Note

Intrinsic Value

The intrinsic value of one AUROPHARMA stock under the Base Case scenario is 1 081.41 INR. Compared to the current market price of 1 223.7 INR, Aurobindo Pharma Ltd is Overvalued by 12%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AUROPHARMA Intrinsic Value
1 081.41 INR
Overvaluation 12%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Aurobindo Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AUROPHARMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AUROPHARMA?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Aurobindo Pharma Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Aurobindo Pharma Ltd

Provide an overview of the primary business activities
of Aurobindo Pharma Ltd.

What unique competitive advantages
does Aurobindo Pharma Ltd hold over its rivals?

What risks and challenges
does Aurobindo Pharma Ltd face in the near future?

Has there been any significant insider trading activity
in Aurobindo Pharma Ltd recently?

Summarize the latest earnings call
of Aurobindo Pharma Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Aurobindo Pharma Ltd.

Provide P/S
for Aurobindo Pharma Ltd.

Provide P/E
for Aurobindo Pharma Ltd.

Provide P/OCF
for Aurobindo Pharma Ltd.

Provide P/FCFE
for Aurobindo Pharma Ltd.

Provide P/B
for Aurobindo Pharma Ltd.

Provide EV/S
for Aurobindo Pharma Ltd.

Provide EV/GP
for Aurobindo Pharma Ltd.

Provide EV/EBITDA
for Aurobindo Pharma Ltd.

Provide EV/EBIT
for Aurobindo Pharma Ltd.

Provide EV/OCF
for Aurobindo Pharma Ltd.

Provide EV/FCFF
for Aurobindo Pharma Ltd.

Provide EV/IC
for Aurobindo Pharma Ltd.

Show me price targets
for Aurobindo Pharma Ltd made by professional analysts.

What are the Revenue projections
for Aurobindo Pharma Ltd?

How accurate were the past Revenue estimates
for Aurobindo Pharma Ltd?

What are the Net Income projections
for Aurobindo Pharma Ltd?

How accurate were the past Net Income estimates
for Aurobindo Pharma Ltd?

What are the EPS projections
for Aurobindo Pharma Ltd?

How accurate were the past EPS estimates
for Aurobindo Pharma Ltd?

What are the EBIT projections
for Aurobindo Pharma Ltd?

How accurate were the past EBIT estimates
for Aurobindo Pharma Ltd?

Compare the revenue forecasts
for Aurobindo Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Aurobindo Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Aurobindo Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Aurobindo Pharma Ltd compared to its peers.

Compare the P/E ratios
of Aurobindo Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Aurobindo Pharma Ltd with its peers.

Analyze the financial leverage
of Aurobindo Pharma Ltd compared to its main competitors.

Show all profitability ratios
for Aurobindo Pharma Ltd.

Provide ROE
for Aurobindo Pharma Ltd.

Provide ROA
for Aurobindo Pharma Ltd.

Provide ROIC
for Aurobindo Pharma Ltd.

Provide ROCE
for Aurobindo Pharma Ltd.

Provide Gross Margin
for Aurobindo Pharma Ltd.

Provide Operating Margin
for Aurobindo Pharma Ltd.

Provide Net Margin
for Aurobindo Pharma Ltd.

Provide FCF Margin
for Aurobindo Pharma Ltd.

Show all solvency ratios
for Aurobindo Pharma Ltd.

Provide D/E Ratio
for Aurobindo Pharma Ltd.

Provide D/A Ratio
for Aurobindo Pharma Ltd.

Provide Interest Coverage Ratio
for Aurobindo Pharma Ltd.

Provide Altman Z-Score Ratio
for Aurobindo Pharma Ltd.

Provide Quick Ratio
for Aurobindo Pharma Ltd.

Provide Current Ratio
for Aurobindo Pharma Ltd.

Provide Cash Ratio
for Aurobindo Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for Aurobindo Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for Aurobindo Pharma Ltd?

What is the current Free Cash Flow
of Aurobindo Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Aurobindo Pharma Ltd.

Business Breakdown

Aurobindo Pharma Ltd., a prominent player in the global generic pharmaceutical market, began its journey in 1986 with a vision to make high-quality medicines accessible to patients around the world. Over the years, the company has transformed into a diversified pharmaceutical powerhouse, producing a wide range of generic formulations, active pharmaceutical ingredients (APIs), and complex generics. Headquartered in Hyderabad, India, Aurobindo leverages robust research and development capabilities, along with an extensive manufacturing footprint that spans several countries, allowing it to cater to diverse markets, including the United States and Europe. With a commitment to quality and regula...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Aurobindo Pharma Ltd

Current Assets 242.1B
Cash & Short-Term Investments 65.9B
Receivables 48.4B
Other Current Assets 127.8B
Non-Current Assets 208.7B
Long-Term Investments 6.7B
PP&E 142.8B
Intangibles 40.8B
Other Non-Current Assets 18.3B
Current Liabilities 122B
Accounts Payable 44.5B
Other Current Liabilities 77.4B
Non-Current Liabilities 30.3B
Long-Term Debt 23.9B
Other Non-Current Liabilities 6.4B
Efficiency

Earnings Waterfall
Aurobindo Pharma Ltd

Revenue
297.2B INR
Cost of Revenue
-125.2B INR
Gross Profit
172B INR
Operating Expenses
-124.9B INR
Operating Income
47.1B INR
Other Expenses
-11.9B INR
Net Income
35.2B INR

Free Cash Flow Analysis
Aurobindo Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Aurobindo Pharma experienced significant growth in Q1 FY '25 with a 10% year-on-year increase in revenue, reaching INR 7,567 crores. The U.S. and European markets performed well, with U.S. revenues at $426 million and Europe achieving EUR 221 million. The company maintained an EBITDA margin of 21.4% and net profit rose by 61% to INR 919 crores. Future prospects are optimistic with the expected ramp-up of the Pen-G plant and a target EBITDA margin of 21-22% for FY '25. Key strategic initiatives include new product launches and expanded market presence to drive continued growth and profitability.

What is Earnings Call?
Fundamental Scores

AUROPHARMA Profitability Score
Profitability Due Diligence

Aurobindo Pharma Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Positive 3-Year Average ROE
55/100
Profitability
Score

Aurobindo Pharma Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.

AUROPHARMA Solvency Score
Solvency Due Diligence

Aurobindo Pharma Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
87/100
Solvency
Score

Aurobindo Pharma Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AUROPHARMA Price Targets Summary
Aurobindo Pharma Ltd

Wall Street analysts forecast AUROPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AUROPHARMA is 1 562.17 INR with a low forecast of 1 237.25 INR and a high forecast of 2 026.5 INR.

Lowest
Price Target
1 237.25 INR
1% Upside
Average
Price Target
1 562.17 INR
28% Upside
Highest
Price Target
2 026.5 INR
66% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AUROPHARMA?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for AUROPHARMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AUROPHARMA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

717B INR

Dividend Yield

0.37%

Description

Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 21,000 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.

Contact

TELANGANA
Hyderabad
Galaxy, Floor 22-24, Plot No. 1, Survey No. 83/1,, Hyderabad Knowledge City,, Raidurg Panmaktha
+914066725000
www.aurobindo.com

IPO

1995-01-19

Employees

21 000

Officers

Vice Chairman & MD
Mr. Kambam Nithyananda Reddy
Whole-Time Director
Mr. Mettu Madan Mohan Reddy
President of Biologics, CEO of Biologics, Vaccines and Peptid & Director
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Chief Financial Officer
Mr. Santhanam Subramanian
COO & Head of Formulations
Mr. Sanjeev Indravadan Dani
President of Technical
Dr. S. Vijaya Kumar
Show More
Head of Investor Relations & Corporate Communications
Mr. Arvind Bothra
Compliance Officer & Company Secretary
Mr. B. Adi Reddy
Senior Vice President of Global Finance & Operations
Mr. G. P. Prasad
Head of Global Finance Operations
Dr. Sudhir Bimal Singhi
Show Less

See Also

Discover More
What is the Intrinsic Value of one AUROPHARMA stock?

The intrinsic value of one AUROPHARMA stock under the Base Case scenario is 1 081.41 INR.

Is AUROPHARMA stock undervalued or overvalued?

Compared to the current market price of 1 223.7 INR, Aurobindo Pharma Ltd is Overvalued by 12%.

Back to Top